Back to Awarded Treatment Trials
Awarded Trial: 09T-1296
Grant ID
09T-1296
Illness
Schizophrenia, Schizoaffective Disorders
Primary Drug/Intervention
Pravastatin
Primary Dosage
40 mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Henderson
Sample Size
60
Duration of Study Period for Each Subject
90
Outcome Measurements
N/A
Results
In a study of pravastatin 40 mg/day, 60 individuals with chronic schizophrenia (average age 44) were randomized to adjunct drug or placebo for 12 weeks. The outcome was assessed by PANSS, SANS, HAM-D, QOL, MATRICS, and measurements of inflammatory markers and cholesterol. At 6 weeks pravastatin produced a significant improvement in positive symptoms (p=0.01) but this missed significance at 12 weeks (p=0.11). There were also some significant cognitive improvement at 6 weeks but not at 12 weeks. As expected, pravastatin improved the person's lipid profiles. It had little effect on inflammatory markers.
Publication
Submitted for publication.
Link
N/A
PI Name
David Henderson
Degree
MD
Center
Freedom Trail Clinic
Institution
Massachusetts General Hospital
Address
25 Staniford Street, 2nd Floor
City or Town
Boston
State or Province
MA
Zip or Postal Code
2114
Country
USA
Email Address
dchenderson@partners.org